Company Description
Corcept Therapeutics Incorporated engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.
It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing’s syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.
The company is also developing relacorilant, which is in phase III clinical trial for the treatment of hypercortisolism; relacorilant combined with nab-paclitaxel which is in phase III clinical trial to treat platinum-resistant ovarian tumors; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; and for treatment for prostate cancer which is in phase II clinical trial.
In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; and miricorilant, which is in phase IIb trial for the treatment of metabolic dysfunction-associated steatohepatitis.
The company was incorporated in 1998 and is headquartered in Redwood City, California.
| Country | United States |
| Founded | 1998 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 500 |
| CEO | Joseph Belanoff |
Contact Details
Address: 101 Redwood Shores Parkway Redwood City, California 94065 United States | |
| Phone | 650 327 3270 |
| Website | corcept.com |
Stock Details
| Ticker Symbol | CORT |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001088856 |
| CUSIP Number | 218352102 |
| ISIN Number | US2183521028 |
| Employer ID | 77-0487658 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Joseph K. Belanoff M.D. | Co-Founder, President, Chief Executive Officer and Director |
| Atabak Mokari | Chief Financial Officer and Treasurer |
| Sean Maduck | President of Endocrinology |
| Dr. William Guyer Pharm.D. | Chief Development Officer |
| Gary Charles Robb J.D. | Chief Business Officer and Secretary |
| Joseph Douglas Lyon | Chief Accounting and Technology Officer |
| Dr. Hazel Hunt Ph.D. | Chief Scientific Officer |
| Amy Flood | Chief Human Resources and Communications Officer |
| Monica Tellado | President of Emerging Markets |
| Roberto W. Vieira | President of Oncology |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 10, 2025 | 144 | Filing |
| Apr 1, 2025 | 144 | Filing |
| Apr 1, 2025 | 144 | Filing |
| Apr 1, 2025 | 144 | Filing |
| Apr 1, 2025 | 144 | Filing |
| Mar 31, 2025 | 144 | Filing |
| Mar 31, 2025 | 144 | Filing |
| Mar 31, 2025 | 8-K | Current Report |
| Mar 10, 2025 | 144 | Filing |
| Mar 4, 2025 | 144 | Filing |